GLOBALLY, HOW FAST IS THE MARKET FOR CROHN'S DISEASE THERAPEUTICS GROWING?
Arizton Advisory & Intelligence
Make Better Decisions With Most Exhaustive, Exclusive & Unique Reports. Leaders in Data Center & Garden Tools Industry.
The global Crohn’s disease therapeutics market is expected to grow at a CAGR of 10.35% from 2022 to 2027.
The Crohn’s disease therapeutics market was valued at USD 12.82 billion in 2021 and is expected to reach USD 23.14 billion by 2027, growing at a CAGR of 10.35% from 2022 to 2027. Crohn's disease is an inflammatory bowel disease (IBD) that causes digestive tract inflammation, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammatory bowel disease treatment market can be segmented into two types, i.e., Crohn's Disease and?Ulcerative Colitis. Among these, Crohn's Disease dominates the global market.
According to Arizton estimates, the prevalence of Crohn's Disease was high in the United States, followed by the UK and China, in 2020. The increasing prevalence of Crohn's Disease is driving the growth of the Crohn's Disease drugs market. According to estimates, one million people were affected with Crohn's Disease in the US in 2019.
Crohn's Disease Therapeutics: Pipeline Scenario
The Crohn's Disease portfolio contains a total of 100+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for Crohn's Disease are in the Phase II stage. Anti-interleukin and integrin antibodies are dominating the Crohn’s Disease drug pipeline.
领英推荐
Crohn's Disease Therapeutics: Clinical Trials Scenario
?The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for Crohn's Disease are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Crohn's Disease have been in the early and mid-phases of development, with 75-80% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of global Crohn's Disease clinical trials.
Reach us at [email protected]